Compare FCBC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | OCS |
|---|---|---|
| Founded | 1874 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.3M | 732.4M |
| IPO Year | 1996 | 2022 |
| Metric | FCBC | OCS |
|---|---|---|
| Price | $48.50 | $12.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 63.7K | ★ 170.1K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.28 | $466.06 |
| Revenue Next Year | $2.55 | $479.73 |
| P/E Ratio | $26.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.21 | $10.52 |
| 52 Week High | $50.17 | $34.48 |
| Indicator | FCBC | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 39.19 |
| Support Level | $47.54 | $10.63 |
| Resistance Level | $49.84 | $13.28 |
| Average True Range (ATR) | 0.91 | 0.39 |
| MACD | -0.18 | -0.09 |
| Stochastic Oscillator | 61.25 | 6.57 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.